Technical Analysis for STAB - Statera Biopharma Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | N/A |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| New 52 Week High | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Bearish Engulfing | Bearish | 31.25% | |
| New 52 Week High | Strength | 31.25% | |
| New 52 Week Closing High | Bullish | 16.67% | |
| Gapped Up | Strength | 16.67% | |
| Gapped Down | Weakness | 35.48% | |
| New 52 Week Closing Low | Bearish | 55.56% | |
| Hot IPO Pullback | Bullish Swing Setup | 55.56% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 3 days ago |
| 2x Volume Pace | 3 days ago |
| Up 5% | 3 days ago |
| Up 3% | 3 days ago |
| Up 10% | 3 days ago |
Get this analysis on your stocks daily!
Statera Biopharma Inc Description
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.
Classification
Keywords: Medicine Medical Specialties Clinical Medicine Biopharmaceutical Infectious Diseases Immunology Cancers Antibodies Autoimmune Diseases Immunotherapy Cancer Treatments Immunotherapies Multiple Sclerosis Fibromyalgia Crohn's Disease Pancreatic Cancer Autoimmunity Inflammatory Virotherapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.045 |
| 52 Week Low | 0.026 |
| Average Volume | 934,354 |
| 200-Day Moving Average | 0.0000 |
| 50-Day Moving Average | 0.0000 |
| 20-Day Moving Average | 0.0000 |
| 10-Day Moving Average | 0.0000 |
| Average True Range | 0.0000 |
| RSI | 0.00 |
| ADX | 0.0 |
| +DI | 0.0000 |
| -DI | 0.0000 |
| Chandelier Exit (Long, 3 ATRs) | N/A |
| Chandelier Exit (Short, 3 ATRs) | N/A |
| Upper Bollinger Bands | 0.0000 |
| Lower Bollinger Band | 0.0000 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.0000 |
| MACD Line | 0.0000 |
| MACD Signal Line | 0.0000 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.0600 | ||||
| Resistance 3 (R3) | 0.0590 | 0.0520 | 0.0570 | ||
| Resistance 2 (R2) | 0.0520 | 0.0474 | 0.0525 | 0.0560 | |
| Resistance 1 (R1) | 0.0470 | 0.0446 | 0.0495 | 0.0480 | 0.0550 |
| Pivot Point | 0.0400 | 0.0400 | 0.0413 | 0.0405 | 0.0400 |
| Support 1 (S1) | 0.0350 | 0.0354 | 0.0375 | 0.0360 | 0.0290 |
| Support 2 (S2) | 0.0280 | 0.0326 | 0.0285 | 0.0280 | |
| Support 3 (S3) | 0.0230 | 0.0280 | 0.0270 | ||
| Support 4 (S4) | 0.0240 |
